Check 35,000+ stocks against 26 valuation models and 37 quality factors

Hikma Pharmaceuticals PLC (HKMPF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Hikma Pharmaceuticals PLC $34.07, price $21.10, upside +61.5%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN GB00B0LCW083

Broad data Sep 24, 2026

Hikma Pharmaceuticals PLC

HKMPF · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $34.07 · Strongly undervalued (+61.5%)

!Quality 54/100

!Mixed Growth (revenue 5y +7.4 %/yr)

✓Solidly profitable · 12.0% net margin (TTM)

✓Moderate debt · generates free cash flow

✓4.0% dividend yield · Sustainable

!Moderate moat 51/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $9.97 – $33.46 · fair‑value band $16.21 – $51.18 · the $21.10 price screens below the $34.07 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Stock analysis

Hikma Pharmaceuticals PLC (HKMPF) currently trades at $21.10, while our model-based Fair Value estimate is $34.07, implying the stock looks roughly 38.1% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of $35.79 per share, and 17 of the 24 models we run sit above the $21.10 price.

Bear case: the Asset-Based group reads lowest at $8.23, and 7 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $16.21 (bear) to $51.18 (bull), the price of $21.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Hikma Pharmaceuticals PLC reported revenue of $3.3B in FY2025 versus $2.6B in FY2021, a compound +7.0%/yr. Reported net income was $411M in FY2025, compounding −0.6%/yr from FY2021.

Key figures

Market cap $4.7B · P/E ratio 11.7 · P/S ratio 1.43 · EPS (TTM) $1.81 · Dividend yield 4.0% · Net margin 12.3% · Return on equity 16.5% · Return on assets (EBIT) 9.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 16% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 61%, HKMPF screens cheaper than that median.

Fair Value models

Bear $16.21 Fair Value $34.07 Bull $51.18

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.7335 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $8.94 $19.06 $35.54 76

Growth DCF $8.87 $18.22 $32.94 75

EPV $14.75 $17.92 $20.65 74

All 24 models by family

DCF Models

FCF DCF $8.94 $19.06 $35.54 76

Owner Earnings $24.81 $46.24 $81.10 73

5Y Revenue Exit $15.68 $32.94 $56.40 70

5Y EBITDA Exit $24.04 $49.82 $82.08 72

5Y P/E Exit $18.87 $39.38 $62.61 68

10Y Revenue Exit $12.33 $27.62 $50.95 63

10Y EBITDA Exit $18.50 $39.57 $71.54 65

10Y P/E Exit $15.18 $32.18 $55.93 61

Earnings-Based

Graham-Dodd $13.21 $56.95 $77.83 64

Lynch FV $14.60 $20.86 $27.12 61

PEG = 1.0 $14.60 $20.86 $27.12 57

EPV $14.75 $17.92 $20.65 74

Multiples

P/E Multiple $32.05 $42.74 $53.42 63

P/S Multiple $24.77 $33.02 $41.28 58

P/B Multiple $24.77 $33.02 $41.28 55

EV/EBIT $29.72 $41.38 $53.05 66

EV/EBITDA $35.36 $48.90 $62.44 67

EV/Revenue $19.70 $30.40 $41.11 53

Asset-Based

NCAV (Graham) $6.14 $8.23 $12.28 54

Growth DCF

Growth DCF $8.87 $18.22 $32.94 75

Rev-Margin DCF $15.68 $32.38 $53.41 70

Economic Profit

Residual Income $12.40 $16.33 $25.33 74

ROIC Compounder $15.77 $22.50 $31.71 71

Growth Earnings

Growth-Adj P/E $25.05 $35.79 $46.53 67

Open the full fair value analysis →

Notify me when HKMPF reaches fair value

Put HKMPF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 54/100

Of which business quality 52 · Market factors (momentum, volatility) 51

Profitability 50

Margins and returns on capital today

Quality Growth 39

Are margins and returns improving?

Cashflow 31

Earnings quality: real cash, not paper profit

Fin. Strength 55

Balance sheet, leverage, solvency risk

Investment 68

Disciplined investing over empire-building

Low Volatility 58

Calm price path (market factor)

Momentum 54

Price trend over the last 3–12 months (market factor)

52W Momentum 39

Distance to the 52-week high (market factor)

Net Issuance 85

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 71/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+7.1%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+10.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.4%

Start year 2020 (pandemic). Over 10 years: +8.8% a year

Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+4.4%

Earnings growth per share plus dividend.

Earnings per share, growth per year+0.4%

Dividend (yield on the price)4.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0.4% vs 3.9%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 17%

2025 sits 116% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+17.9%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+4.1%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +15.2% a year for the price and +1.7% for the forecasts.

Forecast 2026 (sales)+3.5%

Forecast 2027 (sales)+4.8%

Projected 2028 (sales)+4.4%

Projected 2029 (sales)+4.1%

Projected 2030 (sales)+3.7%

Watch HKMPF, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive

Recent news coverage is more positive than average.

Hikma advances its epinephrine nasal spray with multi-market regulatory filings Yahoo Finance · Sep 10, 2026
Hikma Pharmaceuticals (LSE:HIK) Stock Fair Value Edges Higher After Bullish Analyst Targets Yahoo Finance · Sep 5, 2026
Citi sees Hikma discount as unwarranted after upgrade to forecasts Yahoo Finance · Aug 12, 2026
Hikma jumps 10% as brokers point to profit beat and undemanding rating Yahoo Finance · Aug 6, 2026

Compare Hikma Pharmaceuticals PLC with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hikma Pharmaceuticals PLC · Fair Value
$34.07 +38%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/HKMPF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Hikma Pharmaceuticals PLC · Fair Value</span><br><b style="font-size:20px">$34.07</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+38%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Hikma Pharmaceuticals PLC Fair Value". https://www.fairvalue-calculator.com/stock/HKMPF

Frequently asked questions

Is Hikma Pharmaceuticals PLC (HKMPF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $34.07 versus a price of $21.10, about +61% upside (undervalued).

What is the fair value of HKMPF?

Our model-based fair value for Hikma Pharmaceuticals PLC is $34.07 (as of Sep 24, 2026), built from audited fundamentals. The current price: $21.10.

What is the quality score of HKMPF?

Hikma Pharmaceuticals PLC has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Hikma Pharmaceuticals PLC (HKMPF)?

Our model-based price target is the fair value of $34.07 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $16.21, optimistic scenario $51.18. It is a calculation from audited fundamentals, not an analyst target.

What is the Hikma Pharmaceuticals PLC stock forecast for 2026?

Our models put fair value at $34.07, about +61% upside versus a price of $21.10 (undervalued). Cautious scenario $16.21, optimistic scenario $51.18. The calculation is refreshed regularly with new filings.

What is the revenue of Hikma Pharmaceuticals PLC (HKMPF)?

Hikma Pharmaceuticals PLC reported trailing-twelve-month revenue of about $3.3B (latest available figure, as of Sep 24, 2026).

Does Hikma Pharmaceuticals PLC pay a dividend?

Hikma Pharmaceuticals PLC currently shows a dividend yield of about 3.98% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Hikma Pharmaceuticals PLC (HKMPF)?

For today's price to be fair in a discounted-cash-flow model, Hikma Pharmaceuticals PLC would have to grow free cash flow by +17.9 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.4 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of HKMPF use?

Our models discount Hikma Pharmaceuticals PLC at 8.9 %: a base by market capitalisation (mid), damped by beta 0.65, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hikma Pharmaceuticals PLC that is +17.9 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.

How much growth has Hikma Pharmaceuticals PLC (HKMPF) delivered so far?

Over the past 5 years revenue at Hikma Pharmaceuticals PLC grew +7.4 % a year. The price currently implies +17.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Hikma Pharmaceuticals PLC (HKMPF) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Hikma Pharmaceuticals PLC (+17.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Hikma Pharmaceuticals PLC (HKMPF)?

The free-cash-flow yield on the price is 3.52 %: that much free cash flow Hikma Pharmaceuticals PLC produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Hikma Pharmaceuticals PLC (HKMPF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hikma Pharmaceuticals PLC it is $34.07 per share (as of Sep 24, 2026), against a price of $21.10. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Hikma Pharmaceuticals PLC stock overvalued or undervalued in 2026?

As of Sep 24, 2026, HKMPF trades below its calculated fair value: price $21.10, fair value $34.07, a gap of about +61% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of HKMPF?

No. The price is what the market pays today ($21.10); the fair value is what the company's own numbers justify ($34.07). For Hikma Pharmaceuticals PLC the two are $12.97 per share apart. That gap is exactly why we show both numbers side by side.

How much is Hikma Pharmaceuticals PLC worth?

The market values Hikma Pharmaceuticals PLC at about $4.7B (market capitalisation, as of Sep 24, 2026). Per share that is $21.10; our models calculate a fair value of $34.07 per share.

What do the bullish and bearish scenarios say about HKMPF?

Our models span a range for Hikma Pharmaceuticals PLC: cautious scenario $16.21, base $34.07, optimistic $51.18 per share (as of Sep 24, 2026, price $21.10). The range comes from different growth and margin assumptions, not from analyst opinions.

How far is HKMPF from its 52-week high?

Hikma Pharmaceuticals PLC trades at $21.10, about 16% below its 52-week high of $25.21 and 32% above the low of $15.94 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $34.07 is for.

Which stocks are comparable to Hikma Pharmaceuticals PLC?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Hikma Pharmaceuticals PLC stock attractive at the current price?

The data as of Sep 24, 2026: price $21.10, calculated fair value $34.07 (+61%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of HKMPF calculated?

We run Hikma Pharmaceuticals PLC through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $34.07, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Hikma Pharmaceuticals PLC currently trades 38 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Hikma Pharmaceuticals PLC (HKMPF)?

The closing price on Oct 2, 2026 was $21.10. Our model-based fair value is $34.07, about +61% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Hikma Pharmaceuticals PLC right now?

The model range is unusually wide ($16.21 to $51.18). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality.

Where does the earnings growth of Hikma Pharmaceuticals PLC (HKMPF) come from?

Earnings per share at Hikma Pharmaceuticals PLC grew +3.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.9 %, EBIT margin −4.3 %, tax rate −0.2 %, residual (interest, one-offs) +1.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Hikma Pharmaceuticals PLC

How large is the market capitalisation of Hikma Pharmaceuticals PLC (HKMPF)?

The market capitalisation of Hikma Pharmaceuticals PLC is $4.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/E ratio of Hikma Pharmaceuticals PLC (HKMPF)?

The price-to-earnings ratio of Hikma Pharmaceuticals PLC is 11.7. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.

What is the P/S ratio of Hikma Pharmaceuticals PLC (HKMPF)?

The price-to-sales ratio of Hikma Pharmaceuticals PLC is 1.43 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Hikma Pharmaceuticals PLC (HKMPF)?

Earnings per share at Hikma Pharmaceuticals PLC are $1.81 (price ÷ EPS = P/E 11.7). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Hikma Pharmaceuticals PLC (HKMPF)?

The dividend yield of Hikma Pharmaceuticals PLC is 4.0% (payout 46.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Hikma Pharmaceuticals PLC (HKMPF)?

The net margin of Hikma Pharmaceuticals PLC is 12.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Hikma Pharmaceuticals PLC (HKMPF)?

The return on equity (ROE) of Hikma Pharmaceuticals PLC is 16.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Hikma Pharmaceuticals PLC (HKMPF)?

On an EBIT basis the return on assets of Hikma Pharmaceuticals PLC is 9.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Hikma Pharmaceuticals PLC (HKMPF)?

The operating margin of Hikma Pharmaceuticals PLC is 16.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Hikma Pharmaceuticals PLC (HKMPF)?

Revenue at Hikma Pharmaceuticals PLC is growing +8.5% versus a year earlier (3y avg +10.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Hikma Pharmaceuticals PLC (HKMPF)?

Earnings per share at Hikma Pharmaceuticals PLC are growing +23.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Hikma Pharmaceuticals PLC (HKMPF) carry?

The net debt of Hikma Pharmaceuticals PLC is $1.3B (fiscal year 2025, ≈ 8.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.